Can Pfizer Acquisition Of Anacore Be Justified?
Here Is Why Pfizer Acquired Anacore Pharmaceuticals
- Pfizer made failed attempts to acquire AstraZeneca and Allergan. The deals were aimed at tax synergies.
- Changes in US acquisition laws makes such acquisitions difficult.
- As a result, Pfizer intends to build future shareholder by small acquisitions and collaboration to strengthen its drug portfolio. We could expect large number of deals by the end of year.
- The company may split growth and legacy business in future.
- With the motive of strengthening its growth business, Pfizer acquired Anacore Pharmaceuticals @ $99.25 per share for $5.2 B. Pfizer paid a premium of 55% over the existing market price.
- We believe Pfizer paid a reasonable price.
Have more questions about Pfizer? See the links below.
- By What Percentage Did Pfizer’s Revenue & EBITDA Decline In The Last 5 Years?
- Will Pfizer Answer These Two Questions In Its First Quarter Earnings?
- By What Percentage Can Pfizer’s Revenue & EBITDA Grow In The Next 3 Years?
- How Has Pfizer’s Revenue Composition Changed Over The Last 5 Years?
- How Much Additional Synergies Does Pfizer Require To Justify Premium Paid For Allergan?
- Looking At M&A History, What Metrics Suggest That Pfizer Has Been Conservative While Engineering Allergan Deal?
- How Much Revenues Can Pfizer’s Phase 3 Pipeline Add By 2020?
- What’s Pfizer’s Revenue And Earnings Breakdown?
Notes:
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
- This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)